Geranylgeranyl pyrophosphate

Geranylgeranyl pyrophosphate is a metabolite involved in protein geranylgeranylation. Geranylgeranyl pyrophosphate is the common precursor of diterpenoids, for example, Paclitaxel. Geranylgeranyl pyrophosphate can be used for cancer research[1].

Product Specifications

CAS Number

[6699-20-3]

UNSPSC

12352211

Hazard Statement

H225-H301+H311+H331-H370

Target

Endogenous Metabolite

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/geranylgeranyl-pyrophosphate.html

Solubility

10 mM in DMSO

Smiles

O=P(O)(OP(O)(O)=O)OC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/C

Molecular Formula

C20H36O7P2

Molecular Weight

450.44

Precautions

P210-P233-P240-P241-P242-P243-P260-P261-P264-P270-P271-P280-P302+P352-P303+P361+P353-P304+P340-P308+P311-P330-P361+P364-P370+P378-P403+P233-P403+P235-P405-P501

References & Citations

[1]Joseph C Utomo, et al. Developing a Yeast Platform Strain for an Enhanced Taxadiene Biosynthesis by CRISPR/Cas9. Metabolites. 2021 Mar 3;11 (3) :147.|[2] Nakada T, et al. Novel antibody drug conjugates containing exatecan derivative-based cytotoxic payloads. Bioorg Med Chem Lett. 2016 Mar 15;26 (6) :1542-1545. |[3]Kinneer K, et al. Design and Preclinical Evaluation of a Novel B7-H4-Directed Antibody-Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305. Clin Cancer Res. 2023 Mar 14;29 (6) :1086-1101.